FOLH1 and bone metastasis: In addition to that, RALU is a prospective observational study of radium-223/177Lu-PSMA therapy, investigating the feasibility and clinical outcomes of sequential α- and β-emitter (radium-223 and 177Lu-PSMA therapy) use in mCRPC patients with bone metastasis.